Chlorothricin
(Synonyms: 氯丝菌素,Antibiotic K 818A) 目录号 : GC16628
A macrocyclic-type antibiotic
Cas No.:34707-92-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 173, 500, 260, and 120 μM for pyruvate carboxylases from Bacillus, Azotobacter, rat, and chicken, respectively.
Chlorothricin is a macrolide-type antibiotic.
Macrolides, a class of natural products belonging to the polyketide class of natural products, consist of a large macrocyclic lactone ring. The lactone rings are oftem 14-, 15-, or 16-membered. Some macrolides have been reported to have antibiotic or antifungal activity and are widely used as pharmaceutical drugs.
In vitro: In a previous study, chlorothricin was found to inhibit the reaction catalyzed by pyruvate carboxylase from Bacillus stearothermophilus. Moreover, with steady-state kinetic measurements, inhibition of the overall reaction was found to be competitive with the allosteric activator of this enzyme, CoASAc, and non-competitive with respect to both substrates of MgATP and pyruvate. These findings strongly indicated that the site 1conformation of pyruvate carboxylase responsible for the regulation of the overall enzyme activity could be influenced by chlorothricin and CoASAc in an antagonistic manner [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Schindler PW, Zhner H. Mode of action of the macrolide-type antibiotic, chlorothricin. Kinetic study of the inhibition of pyruvate carboxylase from Bacillus stearothermophilus. Eur J Biochem. 1973 Nov 15;39(2):591-600.
| Cas No. | 34707-92-1 | SDF | |
| 别名 | 氯丝菌素,Antibiotic K 818A | ||
| 化学名 | (4S,4aS,6aR,11E,12aR,15R,16aS,21aR,21bR)-4-[[4-O-[3-O-(3-chloro-6-methoxy-2-methylbenzoyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]-1,2,3,4,4a,6a,7,8,9,10,12a,15,16,21,21a,21b-hexadecahydro-22-hydroxy-15,21a-dimeth | ||
| Canonical SMILES | OC([C@]1([C@@]([H])(C=C([C@@H](C1)C)C(O)=O)/C=C\CCCC[C@]2([H])C=C[C@@]3([H])[C@](CCC[C@@H]3O[C@@]([H])(C[C@H]4O)O[C@@H]([C@H]4O[C@@]([H])(C[C@H]5OC(C6=C(OC)C=CC(Cl)=C6C)=O)O[C@@H]([C@H]5O)C)C)([H])[C@@]27C)OC8=O)=C8OC7=O | ||
| 分子式 | C50H63ClO16 | 分子量 | 955.5 |
| 溶解度 | Soluble in ethanol;Soluble in methanol;Soluble in DMSO;Soluble in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.0466 mL | 5.2329 mL | 10.4657 mL |
| 5 mM | 0.2093 mL | 1.0466 mL | 2.0931 mL |
| 10 mM | 0.1047 mL | 0.5233 mL | 1.0466 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。